Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Benefits of Statins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitors for Patients with Peripheral Arterial Disease

Author(s): Kosmas I. Paraskevas*, Debabrata Mukherjee and Theofanis T. Papas

Volume 22, Issue 1, 2024

Published on: 30 November, 2023

Page: [8 - 10] Pages: 3

DOI: 10.2174/0115701611292747231129080204

Price: $65

« Previous Next »
[1]
Horváth L, Németh N, Fehér G, Kívés Z, Endrei D, Boncz I. Epidemiology of peripheral artery disease: Narrative review. Life 2022; 12(7): 1041.
[http://dx.doi.org/10.3390/life12071041] [PMID: 35888129]
[2]
Lin J, Chen Y, Jiang N, Li Z, Xu S. Burden of peripheral artery disease and its attributable risk factors in 204 countries and territories from 1990 to 2019. Front Cardiovasc Med 2022; 9: 868370.
[http://dx.doi.org/10.3389/fcvm.2022.868370] [PMID: 35498034]
[3]
Paraskevas KI, Shearman CP. Ask the expert: Assessment of peripheral vascular disease in primary care. BMJ 2023; 381: 605.
[http://dx.doi.org/10.1136/bmj.p605] [PMID: 37160326]
[4]
Daskalopoulou SS, Pathmarajah M, Kakkos SK, et al. Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J 2008; 72(3): 441-8.
[http://dx.doi.org/10.1253/circj.72.441] [PMID: 18296843]
[5]
Xu C, Tian Q, Yu H, Ge W, Zheng H, Huang D. Predictive value of the ankle-brachial index for all-cause and cardio-cerebrovascular mortality. Angiology 2023; 74(7): 649-56.
[http://dx.doi.org/10.1177/00033197221121016] [PMID: 36052942]
[6]
Alnaeb ME, Alobaid N, Seifalian AM, Mikhailidis DP, Hamilton G. Statins and peripheral arterial disease: Potential mechanisms and clinical benefits. Ann Vasc Surg 2006; 20(5): 696-705.
[http://dx.doi.org/10.1007/S10016-006-9104-1] [PMID: 16841271]
[7]
Katsiki N, Giannoukas AD, Athyros VG, Mikhailidis DP. Lipid-lowering treatment in peripheral artery disease. Curr Opin Pharmacol 2018; 39(2): 19-26.
[http://dx.doi.org/10.1016/j.coph.2018.01.003] [PMID: 29413998]
[8]
Alnaeb ME, Youssef F, Mikhailidis DP, Hamilton G. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology 2006; 57(1): 65-71.
[http://dx.doi.org/10.1177/000331970605700109] [PMID: 16444458]
[9]
Soudet S, Bultel L, Adnane L, Reix T, Sevestre MA. Under-prescription of medical treatment for peripheral artery disease in the under 50s: A retrospective study. Angiology 2022; 73(4): 338-43.
[http://dx.doi.org/10.1177/00033197211042155] [PMID: 34486390]
[10]
Vila MM, Igual L, Remeseiro B, et al. Polyvascular subclinical atherosclerosis: Correlation between ankle brachial index and carotid atherosclerosis in a population-based sample. Angiology 2023; 74(5): 443-51.
[http://dx.doi.org/10.1177/00033197221110720] [PMID: 35758047]
[11]
Aboyans V, Ricco JB, Bartelink MLEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for vascular surgery (ESVS). Eur Heart J 2018; 39(9): 763-816.
[http://dx.doi.org/10.1093/eurheartj/ehx095] [PMID: 28886620]
[12]
Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease. J Am Coll Cardiol 2017; 69(11): e71-e126.
[http://dx.doi.org/10.1016/j.jacc.2016.11.007] [PMID: 27851992]
[13]
Daskalopoulou S, Daskalopoulos M, Liapis C, Mikhailidis D. Peripheral arterial disease: A missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 2005; 12(4): 443-52.
[http://dx.doi.org/10.2174/0929867053363009] [PMID: 15720252]
[14]
Paraskevas KI, Suri JS, Saba L, Mikhailidis DP. Combination therapy with ezetimibe: An alternative strategy to statin monotherapy in the management of patients with non-cardiac vascular disease. Curr Vasc Pharmacol 2022; 20(6): 457-9.
[http://dx.doi.org/10.2174/1570161120666220919095729] [PMID: 36121079]
[15]
Dicembrini I, Giannini S, Ragghianti B, Mannucci E, Monami M. Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: A systematic review and meta-analysis of randomized controlled trials. J Endocrinol Invest 2019; 42(9): 1029-39.
[http://dx.doi.org/10.1007/s40618-019-01019-4] [PMID: 30762200]
[16]
Cowart K, Singleton J, Carris NW. Inclisiran for the treatment of hyperlipidemia and for atherosclerotic cardiovascular disease risk reduction: A narrative review. Clin Ther 2023; 45(11): 1099-104.
[http://dx.doi.org/10.1016/j.clinthera.2023.06.011]
[17]
Hadi NR, Saud A, Ali N, Gali F, Qassam H. The effect of evolocumab alone and in combination with atorvastatin on atherosclerosis progression and TLRs expression. J Med Life 2023; 16(5): 759-65.
[http://dx.doi.org/10.25122/jml-2021-0210] [PMID: 37520489]
[18]
Schwartz GG, Steg PG, Szarek M, et al. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome. Circulation 2020; 141(20): 1608-17.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.046524] [PMID: 32223446]
[19]
Clavijo LC, Caro J, Choi J, et al. The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study). Cardiovasc Revasc Med 2023; 55: 52-6.
[http://dx.doi.org/10.1016/j.carrev.2023.04.020] [PMID: 37142533]
[20]
Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol 2013; 771: 42-50.
[http://dx.doi.org/10.1007/978-1-4614-5441-0_6] [PMID: 23393670]
[21]
Luan J, Xu J, Zhong W, Zhou Y, Liu H, Qian K. Adverse prognosis of peripheral artery disease treatments associated with diabetes: A comprehensive meta-analysis. Angiology 2022; 73(4): 318-30.
[http://dx.doi.org/10.1177/00033197211042494] [PMID: 34544306]
[22]
Paraskevas KI, Veith FJ, Liapis CD, Mikhailidis DP. Perioperative/periprocedural effects of statin treatment for patients undergoing vascular surgery or endovascular procedures: an update. Curr Vasc Pharmacol 2013; 11(1): 112-20.
[http://dx.doi.org/10.2174/157016113804547656] [PMID: 22272894]
[23]
Paraskevas KI, Gloviczki P, Antignani PL, et al. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease. Prog Cardiovasc Dis 2022; 73(4): 41-7.
[http://dx.doi.org/10.1016/j.pcad.2022.05.003] [PMID: 35605696]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy